Fluoxetine-rapid dissolve - Autism Therapeutics

Drug Profile

Fluoxetine-rapid dissolve - Autism Therapeutics

Alternative Names: AT 001 - Autism Thereapeutics; AT001 - Autism Therapeutics; NPL-2008; ODT fluoxetine - Autism Therapeutics; Serelsa; Zydis™ ODT fluoxetine

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mount Sinai School of Medicine
  • Developer Autism Therapeutics
  • Class Antidepressants; Eye disorder therapies; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autistic disorder
  • New Molecular Entity No

Highest Development Phases

  • Phase III Autistic disorder

Most Recent Events

  • 19 Sep 2017 Fluoxetine-rapid dissolve is still at phase III development stage for Autistic disorder (in adolescents and children) and at phase II development stage (in adults) in USA (PO) (Autism Therapeutics pipeline, September 2017)
  • 27 May 2015 Phase III development for Autistic disorder (In Children, In adolescents) is ongoing in the USA
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top